FULC (Fulcrum Therapeutics) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FULC Fulcrum Therapeutics Inc FULC
44 GF Score
Price $3.73
GF Value $32.03
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Fulcrum Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FULC vs AGEN, IRD, TTRX: Short Interest Comparison

For the Biotechnology subindustry, Fulcrum Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulcrum Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Fulcrum Therapeutics's Short Interest falls into.


FULC
44GF Score
Fulcrum Therapeutics Inc FULC
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fulcrum Therapeutics (FULC) Overvalued in 2026?

Based on GuruFocus' analysis, Fulcrum Therapeutics stock appears to be undervalued. The current stock price of $3.73 is trading 88.4% below its estimated GF Value™ of $32.03. GuruFocus considers Fulcrum Therapeutics to be Possible Value Trap.

Key valuation signals for FULC:

  • Short Interest:
  • GF Value™: $32.03 vs. price of $3.73 (88.4% below fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the FULC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fulcrum Therapeutics Business Description

Address 26 Landsdowne Street, Cambridge, MA, USA, 02139
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
44GF Score

Get the complete analysis for FULC

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.73
Price
$32.03
GF Value